XML 18 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Insider Trading Arrangements
 3 Months Ended
Jun. 30, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

Trading Arrangements

During our last fiscal quarter, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.

 

 

 

 

 

 

 

 

 

 

 

Type of Trading Arrangement

 

 

 

Name and Position

Action

Adoption/ Termination

Date

Rule 10b5-1*

Non-Rule 10b5-1**

Total Shares of Common Stock to be Sold

Total Shares of Common Stock to be Purchased

Expiration Date

Robert Janssen, M.D.,

Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs

Adoption

May 30, 2024

X

 

311,535 shares of common stock underlying stock options

 

September 12, 2025, unless earlier terminated as outlined in the plan

* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.

Name Robert Janssen
Title M.D.,Chief Medical Officer and Senior Vice President
Rule 10b5-1 Arrangement Adopted true
Adoption Date May 30, 2024
Expiration Date September 12, 2025
Arrangement Duration 471 days
Aggregate Available 311,535